Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan Chemotherapy is evolving to include biomarker-driven remedies predicated on the molecular mutations of tumours, finds Frost & Sullivan A vast number and selection of remedies are steadily signing up for the treatment pipeline for colorectal cancers. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the marketplace. To stay competitive, individuals are focussing on determining new targets, enhancing general survival at the early treatment stage, and reducing toxicity. New analysis from Frost & Sullivan, Pipeline and Product Evaluation of the Global Colorectal Tumor Market, discovers that advanced targeted therapies are dominating the colorectal cancer tumor pipeline, accounting for 60 % of the medicines under development.The young children are confounded by the visual world around them, however: Asked to draw a bicycle, they will show all the parts, but strew them randomly across the page . This strange mix of mental valleys and peaks drew Korenberg and Bellugi to the disorder. ‘Williams syndrome presents a unique lens for finding the how genes form the brain circuitry in charge of human being behavior,’ explains Korenberg. This prompted Korenberg’s collaboration with Bellugi, who’s thinking about the cognitive areas of the disorder, ‘Genetic contributions to individual cognition and behavior are clear but tough to define,’ says Bellugi.